Delayed Initiation of Treatment Is Associated With Metastasis of Malignant Bone Tumor

Abstract Background Karyopherin α 2 (KPNA2), a member of the Karyopherin α family, has been observed in several cancers but lack substantial investigation in malignant bone tumors. The purpose of the current study was to evaluate KPNA2 expression level and its utility as a novel diagnostic biomarker in osteosarcomas and their malignant bone tumor mimickers, such as chondrosarcomas and Ewing sarcomas.Method We investigated the expression of KPNA2 protein by immunohistochemistry on paraffin embedded surgical specimens from 217 patients with malignant and benign tumors of bone, including 81 osteosarcomas, 42 chondrosarcomas, 9 Ewing sarcomas, 28 osteoid osteoma, 20 osteochondroma and 37 Chondroblastoma. Immunoreactivity was scored semi quantitatively based on stain extent and intensity.Results Seventy one of 81 (87.7%) osteosarcomas, zero of 42 (0%) chondrosarcomas and one of 9 (11.1%) Ewing sarcomas showed immunoreactivity for KPNA2. Negative KPNA2 expression was observed in all of benign bone tumors. Much more positive expression of KPNA2 was found in osteosarcomas as compared with chondrosarcomas and Ewing sarcomas. The sensitivity and specificity of KPNA2 immuno-expression for osteosarcoma was 87.7% and 100%, respectively. In several subtypes of osteosarcomas, immunohistochemical expression of KNA2 was more frequent in osteoblastic (94.5%), with 39 (70.9%) showing strong-intensity staining. KPNA2 positivity was observed in eleven of 13 (84.6%) chondroblastic, three of 6 (50%) fibroblastic, three of 4 (75%) telangiectatic and two of 3 (66.7%) giant cell-rich osteosarcoma. Stronger-intensity staining was observed in osteoblastic osteosarcoma.Conclusion KPNA2 is most frequently expressed in osteosarcomas, particularly in osteoblastic and chondroblastic tumors, but is rarely positive in chondrosarcomas and Ewing sarcomas. This feature may have diagnostic value since it is very useful for distinguishing between osteosarcomas and other bone sarcomas mimickers. This report supports KPNA2 as a novel marker for the diagnosis of osteosarcoma.

Download Full-text

Sensitive Osteosarcoma Diagnosis Through Five-Base Telomerase Product-Triggered CRISPR-Cas12a Enhanced Rolling Circle Amplification

Analytical Methods ◽

10.1039/d1ay00952d ◽

2021 ◽

Author(s):

Xing Zhou ◽

Jun-Liang Zhang ◽

Meng-Han Chang ◽

Gentao Fan ◽

Xiao-Zhou Liu ◽

...

Keyword(s):

Early Diagnosis ◽

Bone Tumor ◽

Rolling Circle Amplification ◽

Mesenchymal Cells ◽

Pivotal Role ◽

Sensitive Detection ◽

Malignant Bone Tumor ◽

Rolling Circle ◽

Primary Malignant Bone Tumor

Osteosarcoma is the most frequent primary malignant bone tumor composed of mesenchymal cells producing osteoid and immature bone. Sensitive detection of telomerase plays a pivotal role for the early diagnosis...

Download Full-text

Bone Scintigraphy in Primary Malignant Bone Tumor

Nuclear Medicine in Clinical Oncology ◽

10.1007/978-3-642-70947-0_17 ◽

1986 ◽

pp. 108-114 ◽

Cited By ~ 1

Author(s):

H. Creutzig

Keyword(s):

Bone Scintigraphy ◽

Bone Tumor ◽

Malignant Bone Tumor ◽

Primary Malignant Bone Tumor

Download Full-text

Arthrodeses After Malignant Bone Tumor Resection in Children

Limb Salvage ◽

10.1007/978-3-642-75879-9_76 ◽

1991 ◽

pp. 543-551

Author(s):

R. Capanna ◽

M. Manfrini ◽

D. Donati ◽

A. Ferruzzi ◽

M. Campanacci

Keyword(s):

Bone Tumor ◽

Tumor Resection ◽

Malignant Bone Tumor ◽

Bone Tumor Resection

Download Full-text

Association of The Cytotoxic T Lymphocyte Antigen-4 +49G/A Gene Polymorphism with Susceptibility to Malignant Bone Tumors

10.21203/rs.3.rs-54235/v1 ◽

2020 ◽

Author(s):

Ningfeng Guo ◽

Yaojun Wu ◽

Yueming Hu

Keyword(s):

T Lymphocyte ◽

Bone Tumor ◽

Bone Tumors ◽

Cytotoxic T Lymphocyte ◽

Meta Analysis ◽

Population Based ◽

Cochrane Library ◽

Malignant Bone Tumor ◽

Malignant Bone Tumors ◽

Lymphocyte Antigen

Abstract Background Earlier research works have studied the part that cytotoxic T-lymphocyte antigen-4 (CTLA-4) plays in the carcinogenesis of malignant bone tumors, nonetheless, findings had inconsistency. The current investigation aims at clarifying the association between CTLA-4 polymorphism and malignant bone tumor susceptibility through the meta-analysis.Methods We searched pertinent research works in not just PubMed, but also EMBASE, Cochrane library, and Chinese National Knowledge Infrastructure (CNKI) databases in humans published before October 2019. The use of the pooled odds ratio (OR) with its 95% confidence interval (95%CI) was made for estimating the strengths of the correlation existing between the CTLA-4 genetic polymorphism and malignant bone tumors susceptibility. An aggregate of six research works with 1191 malignant bone tumors patients and 1418 controls were selected eventually. The pooled results shed light on the fact that CTLA-4 +49G/A polymorphism had a significant correlation with an augmented vulnerability to the malignant bone tumors (A vs. G: OR=1.37, 95%CI=1.22-1.54; GA vs. GG: OR=1.20, 95%CI=1.01-1.42; AA vs. GG: OR=2.13, 95%CI=1.63-2.78; GA+AA vs. GG: OR=1.35, 95%CI=1.15-1.59; AA vs. GG+GA: OR=2.02, 95%CI=1.60-2.56). Subgroup analysis indicated that there exists a statistically significant correlation between CTLA-4 +49G/A polymorphism and augmented susceptibility to the malignant bone tumor in the population-based or hospital-based samples, and Ewing’s sarcoma or osteosarcoma. Moreover, there was also not observed any considerable heterogeneity across the research works. Results Our results suggest that the CTLA-4 +49G/A polymorphism may play a pivotal part in the carcinogenesis of malignant bone tumors. Conclusions More research works, on the basis of the large sample sizes as well as homogeneous specimens, are needed in order to verify these results.

Download Full-text